Clearing amyloid plaque from the brain involves both your body’s built-in waste removal system and, in some cases, newer medical treatments. Your brain already has a cleaning mechanism called the glymphatic system that flushes out amyloid proteins, mostly while you sleep. The challenge is that this system slows down with age and certain health conditions, allowing plaque to accumulate. The good news: specific lifestyle changes can boost your brain’s natural clearance, and FDA-approved medications now exist that actively strip plaque from brain tissue.
How Your Brain Clears Plaque Naturally
Your brain has its own waste disposal network called the glymphatic system. It works by pumping cerebrospinal fluid through channels that run alongside blood vessels. This fluid mixes with the fluid already surrounding your brain cells, picks up metabolic waste (including amyloid proteins), and carries it out for disposal. The whole process is driven by specialized cells called astrocytes, which act like gatekeepers using water channels on their surface to control the flow.
Several forces keep this fluid moving. The pulsing of your arteries pushes cerebrospinal fluid deeper into brain tissue. Your breathing and heartbeat create additional pressure waves. Even synchronized electrical activity across networks of brain cells generates rhythmic waves that help flush waste outward. When any of these drivers weaken, whether from aging, diabetes, or other conditions, plaque clearance slows and amyloid starts to build up.
Deep Sleep Is When Most Cleaning Happens
The glymphatic system’s activity spikes dramatically during sleep, specifically during deep slow-wave sleep (the third stage of non-REM sleep). During this stage, slow oscillatory brain waves create a surge of cerebrospinal fluid into the spaces between brain cells, increasing waste clearance by 80 to 90 percent compared to when you’re awake.
The reason is partly mechanical. When you fall asleep, levels of the stress chemical norepinephrine drop, causing the spaces between brain cells to physically expand. During wakefulness, these interstitial spaces occupy about 13 to 15 percent of brain volume. During sleep, they expand to 22 to 24 percent, dramatically reducing resistance to fluid flow. Think of it like opening a clogged drain: the wider the channel, the faster waste flushes out. This is why chronic poor sleep is considered a significant risk factor for amyloid accumulation.
To maximize deep sleep, consistent sleep schedules matter more than total hours. Sleeping on your side may also help, as some research suggests lateral sleeping positions improve glymphatic flow compared to sleeping on your back or stomach. Alcohol, while sedating, actually suppresses slow-wave sleep and should be avoided close to bedtime if brain clearance is a priority.
Exercise Changes How Amyloid Is Produced
Aerobic exercise doesn’t just improve general brain health. It directly alters the chemical pathway that creates amyloid plaque in the first place. Physical activity increases levels of a growth factor called BDNF in the brain. BDNF shifts how a key protein (amyloid precursor protein) gets processed by enzymes. Instead of being cut into toxic amyloid fragments that clump into plaques, the protein gets processed into a protective fragment that actually blocks amyloid production.
In animal studies, running increased levels of this protective fragment in the hippocampus (the brain’s memory center) while simultaneously reducing levels of both major forms of toxic amyloid. When researchers tested BDNF directly on human neural cells in the lab, it reduced secretion of the harmful amyloid fragments by about 18 percent and increased the protective fragment by 12.5 percent. The protective fragment also directly inhibits the enzyme responsible for producing toxic amyloid, creating a reinforcing cycle: more exercise leads to more BDNF, which leads to less amyloid production and more active suppression of the enzyme that makes it.
Most studies showing cognitive benefits use moderate aerobic exercise (brisk walking, cycling, swimming) for at least 150 minutes per week. The effects on BDNF appear to be dose-dependent, meaning more consistent exercise produces stronger results over time.
Diet Patterns Linked to Lower Plaque Levels
Research from the National Institute on Aging found that people who followed the MIND diet or Mediterranean diet had fewer signs of Alzheimer’s pathology in their brains at autopsy, primarily due to lower levels of amyloid plaques. Interestingly, neither diet was linked to fewer tau tangles (the other hallmark protein of Alzheimer’s), suggesting these eating patterns specifically influence amyloid accumulation.
The MIND diet emphasizes leafy greens, berries, nuts, whole grains, fish, and olive oil while limiting red meat, butter, cheese, pastries, and fried food. It was designed specifically for brain health by combining elements of the Mediterranean and DASH diets. You don’t need to follow it perfectly. Studies have shown that even moderate adherence is associated with measurable differences in brain pathology.
What About Fasting and Autophagy?
Fasting triggers a cellular recycling process called autophagy, which breaks down damaged proteins and cellular debris. This has led to popular claims that intermittent fasting can clear brain plaque. The reality is more complicated. In Alzheimer’s mouse models, fasting did activate autophagy in neurons, increasing both the number and size of the cellular structures responsible for breaking down waste. But the activated recycling machinery was insufficient to degrade amyloid that had already accumulated. Fasting actually increased intracellular amyloid buildup, likely because neurons absorbed more amyloid from their surroundings but couldn’t break it down fast enough.
This doesn’t mean fasting is harmful to brain health overall, but the evidence does not support it as a strategy for clearing existing amyloid plaque.
FDA-Approved Medications That Remove Plaque
Two antibody-based medications are now approved to actively remove amyloid plaque from the brain. These represent the first treatments that target the underlying pathology of Alzheimer’s rather than just managing symptoms.
Lecanemab works by binding to amyloid proteins before and after they form plaques. In a large clinical trial published in the New England Journal of Medicine, participants who received the drug over 18 months showed a reduction in brain amyloid burden of about 59 centiloids (a standard unit for measuring plaque on brain scans) compared to placebo. This translated to a modest but statistically significant slowing of cognitive decline.
Donanemab takes a slightly different approach. It targets a modified form of amyloid found specifically in established plaques. By binding to this form, it activates the brain’s immune cells (microglia), which then engulf and clear the plaque deposits from around neurons. Clinical trials in 2024 confirmed significant reductions in amyloid levels. Both medications are given as intravenous infusions and are currently approved only for people with mild cognitive impairment or early-stage Alzheimer’s, not for prevention in healthy individuals.
These treatments carry risks, including brain swelling and small brain bleeds detected on MRI scans, which are usually mild but require monitoring. They also require confirmation of amyloid plaque through PET imaging or spinal fluid testing before starting treatment.
Experimental Approaches Showing Promise
One of the more surprising findings in recent years involves 40 Hz sensory stimulation, using flickering lights and clicking sounds at a specific frequency (40 times per second) that matches the brain’s natural gamma rhythm. In Alzheimer’s mouse models, one hour of this stimulation reduced amyloid burden compared to stimulation at other frequencies or no stimulation at all. A 2024 study published in Nature revealed the mechanism: the 40 Hz stimulation promotes cerebrospinal fluid influx and interstitial fluid drainage in the brain’s cortex, essentially boosting glymphatic clearance through the same water channels that astrocytes use during deep sleep. Human trials are underway but have not yet confirmed the same plaque-reducing effects in people.
Another experimental technique uses focused ultrasound guided by MRI to temporarily open the blood-brain barrier in targeted regions. In a small proof-of-concept trial at West Virginia University, three participants with early Alzheimer’s received monthly ultrasound treatments combined with an anti-amyloid drug. The ultrasound increased drug delivery to targeted brain regions by five to eight times compared to untreated areas. Even without a drug, previous studies found that focused ultrasound alone produced modest reductions in local amyloid levels, possibly by allowing the body’s own immune system better access to brain tissue.
How Brain Plaque Is Measured
If you’re wondering whether you have amyloid plaque, the gold standard is an amyloid PET scan, which uses a radioactive tracer that binds to plaque and makes it visible on imaging. These scans are particularly sensitive for detecting early Alzheimer’s pathology, even in people with only mild cognitive changes. Blood tests that measure amyloid levels are also emerging as a less invasive screening option, though PET imaging remains more precise for guiding treatment decisions. Tau PET scans, which measure a different protein, are better for tracking how far the disease has progressed rather than detecting it early.
For most people concerned about brain plaque, the practical starting point is optimizing the lifestyle factors you can control: prioritizing deep sleep, maintaining consistent aerobic exercise, and following a brain-supportive diet. These strategies work by supporting the glymphatic system and reducing amyloid production at the source, two processes that remain active throughout your life and respond meaningfully to behavioral changes at any age.